Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | HTR1D | P28221 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR1E | P28566 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143976 | 0.80 | KIF11 (0.38) | MAPTMEN1KMT2A | |
| SCHEMBL14663993 | 0.77 | HTR2A (0.59) | SMN1; SMN2KDM4EMAPTPOLBAPAF1 | |
| SCHEMBL24729149 | 0.74 | HTR2A (0.64) | SMN1; SMN2KDM4EMAPTPOLBAPAF1 | |
| SCHEMBL7053677 | 0.74 | HTR2A (0.60) | SMN1; SMN2KDM4EMAPTPOLBAPAF1 | |
| SCHEMBL707958 | 0.72 | HTR2A (0.70) | SMN1; SMN2KDM4EMAPTPOLBAPAF1 | |
| SCHEMBL5692300 | 0.72 | HTR2A (0.70) | SMN1; SMN2KDM4EMAPTPOLBAPAF1 | |
| SCHEMBL9279873 | 0.71 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM4EMAPTPOLBAPAF1 | |
| SCHEMBL7144865 | 0.71 | TAAR1 (0.40) | SMN1; SMN2KDM4EMAPTHTR1AADRA2A | |
| SCHEMBL29530931 | 0.70 | KDM4E (0.69) | SMN1; SMN2KDM4EMAPTPOLBAPAF1 | |
| SCHEMBL24301434 | 0.70 | KDM4E (0.69) | SMN1; SMN2KDM4EMAPTPOLBAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065146-A1 | Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing | COOK PHILLIP D (US) | 2003-04-03 | — | — | US | disclosed |
| US-6448373-B1 | INHIBITORS OF ENZYMES SUCH AS PHOSPHOLIPASE A2; TREATMENT OF INFLAMMATORY DISEASES INCLUDING ATOPIC DERMATITIS AND INFLAMMATORY BOWEL DISEASE | ISIS PHARMACEUTICALS, INC. | 2002-09-10 | — | — | US | disclosed |
| EP-0739351-B1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS INC (US) | 2002-04-10 | — | — | EP | disclosed |
| US-5886177-A | ETHYLENE GLYCOL MONOMERS JOINED VIA STANDARD PHOSPHATE LINKAGES INCLUDING PHOSPHOROTHIOATE, PHOSPHODIESTER, AND PHOSPHORAMIDATE LINKAGES; USEFUL FUNCTIONAL GROUPS INCLUDE NUCLEOBASES AS WELL AS POLAR GROUPS, HYDROPHOBIC GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0739351-A4 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS INC (US) | 1998-10-21 | — | — | EP | disclosed |
| EP-0739351-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| WO-1995018820-A1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065146-A1 | Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing | BPGM, PPIP5K2, PGM2 | SMN1; SMN2 3732/4885KDM4E 4696/4885MAPT 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.